Relapsing Multiple Sclerosis (RMS)

Neurology·MeSH: Multiple Sclerosis

Prevalence

120.0 / 100K

Incidence

7.0 / 100K/yr

9 drugs in development·4 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(8)

Drug	Company
ofatumumab approved dose	Novartis AG (NVS)
Ofatumumab approved dose	Novartis AG (NVS)
ofatumumab new dose	Novartis AG (NVS)
Ofatumumab new dose	Novartis AG (NVS)
ozanimod	CELGENE CORP /DE/ (CELG)
Ublituximab	TG THERAPEUTICS, INC. (TGTX)
Ublituximab IV Simplified Dosing Schedule	TG THERAPEUTICS, INC. (TGTX)
Ublituximab Subcutaneous	TG THERAPEUTICS, INC. (TGTX)

Phase 1(1)

Drug	Company
CABA-201	Cabaletta Bio, Inc. (CABA)

BioSniper tracks 9 drugs in development for Relapsing Multiple Sclerosis (RMS) across 4 companies.

There are 4 clinical trials targeting Relapsing Multiple Sclerosis (RMS) tracked by BioSniper.

The estimated prevalence of Relapsing Multiple Sclerosis (RMS) is approximately 120.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.